McGrath Lynne Fahey's Form 4 filing
Alzamend Neuro, Inc. (ALZN) · filed Apr 6, 2022
- Accession no.
- 0001214659-22-004914
- Filed
- Apr 6, 2022
- Trade date
- Mar 28, 2022
- Filing delay
- 9 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market sales total $30.3K. It was filed 9 days after the trade, past the 2-business-day deadline.
This filing was later replaced by the amendment 0001214659-22-004992 (Apr 8, 2022). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| McGrath Lynne FaheyCIK 0001866270 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 28, 2022 | Common Stock | SSaleAcquired | +25,000 | $1.21F1 | +$30,250 | 75,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average purchase price of $1.213. The range of sale prices on the transaction date was $1.19 to $1.23 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price.
Referenced by the price of 1 transaction in Table I.